¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Agents primarily affecting the gastrointestinal system"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¿µ¹® digestive system ÇÑ±Û ¼ÒÈ­±â°èÅë
¼³¸í   
  ¸ÔÀº À½½ÄÀÇ ºÐÇØ, ¼ÒÈ­, Èí¼ö¿¡ °ü°èµÈ Àå±â¸¦ ÅëÄªÇØ¼­ ºÎ¸£´Â ¸».
¿µ¹® nervous system ÇÑ±Û ½Å°æ°è
¼³¸í   
  ¿©·¯ ±â°üµéÀÇ ¼­·Î°£ »óÈ£¿¬°áü°è°¡ ¹Ù·Î ½Å°æ°èÀÌ´Ù. ¿©±â¿¡´Â ÁßÃ߽Űæ°è(central nerve system: CNS)¿Í ¸»ÃʽŰæ°è(peripheral nerve system: PNS)°¡ Àִµ¥, ÁßÃ߽Űæ°è¶õ ³ú¿Í Ã´¼ö¸¦ ¸»ÇÑ´Ù. ±×¸®°í ¸»ÃʽŰæ°è¿¡´Â 12½ÖÀÇ ³ú½Å°æ(cranial nerve: ³ú¿¡¼­ ±â½ÃÇÏ¿© ÁַΠ¾ó±¼ºÎÀ§¿Í ¸ñ ºÎÀ§¿¡ ºÐÆ÷ÇÑ´Ù)°ú 31½ÖÀǠô¼ö½Å°æ(spinal nerve:spinal cord¿¡¼­ °¢±â ¾çÂÊÀ¸·Î ½ÖÀ» ÀÌ·ç¾î ³ª¿À´Âµ¥ ÁַΠ¸ñÀÌÇϺÎÀ§ÀÇ ½Åü °¢ºÎºÐÀ¸·Î ºÐÆ÷ÇϰԠµÈ´Ù)À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù.
  
  ¶ÇÇÑ ¸»ÃʽŰæ°è´Â 3°¡ÁöÀÇ ½Å°æÁ¶Á÷µé·Î ±¸¼ºµÇ¾î Àִµ¥ ¾Õ¿¡¼­ ¸»ÇÑ ³ú½Å°æ°ú Ã´¼ö½Å°æ¿Ü¿¡ ÀÚÀ²½Å°æ°è°¡ ¿©±â¿¡ ÇØ´çµÈ´Ù. ÀÚÀ²½Å°æ°è´Â ´Ù½Ã ±³°¨½Å°æ°ú ºÎ±³°¨½Å°æÀ¸·Î ³ª´µ¾îÁ® ¼­·Î°£ÀÇ ¿Ã¹Ù¸¥ »óÈ£ÀÛ¿ëÀ¸·Î »ýü ¿©·¯ °¡Áö ÀÛ¿ëÀ» ¼öÇàÇÑ´Ù.
¿µ¹® cardiovascular system ÇÑ±Û ½ÉÀåÇ÷°ü°è
¼³¸í   
  ½ÅüÀÇ Ç÷¾×¼øÈ¯À» ´ã´çÇϴ ±â°ü. Áï ½ÉÀå°ú Ç÷°üÀ» ÅëÄªÇØ¼­ À̸£´Â ¸»ÀÌ´Ù.
¿µ¹® autonomic nervous system ÇÑ±Û ÀÚÀ²½Å°æ°è
¼³¸í   
  »ç¶÷ÀÇ ÀÇÁö¿Í °ü°è¾øÀÌ, Ä§À» È긮°Å³ª ¼ÒÈ­¿îµ¿ µî°ú °°Àº ½º½º·Î Á¶Á¤ÀÌ µÇ¾î ¿òÁ÷À̴ ½Å°æ°èÀ̸砿©±â¿¡´Â ´ÙÀ½°ú °°Àº µÎ °¡Áö°¡ ÀÖ´Ù.
  
  1.±³°¨½Å°æ°è(sympathetic nervous system)-»ç¶÷ÀÌ À§Çè»óÅ¿¡ À̸£·¶À» °æ¿ì¿¡ ÈïºÐÀÌ µÇ´Â ÀÚÀ²½Å°æ°è. ÁɹڼöÀÇ Áõ°¡, ¼ÒÈ­±â ¿îµ¿ÀÇ °¨¼Ò µîÀÇ ÀÏÀÌ À̰÷À» ÅëÇØ¼­ ÀϾ´Ù. ±³°¨½Å°æÀÌ ÈïºÐµÇ¸é ±³°¨½Å°æÀÇ ¸»´Ü¿¡¼­ epinephrine, norepinephrine µîÀÇ ¹°ÁúÀÌ ºÐºñµÇ°í À̰͵鿡 ÀÇÇØ¼­ ¸»ÃÊÀå±â°¡ º¯È­¸¦ ÀÏÀ¸Å²´Ù. ÇÏÁö¸¸ Àå±â¿¡ µû¶ó¼­ epinephrineÀ̳ª norepinephrineÀÇ ¼ö¿ëü¸¦ °¡Áö°í À־ ¿©·¯ °¡Áö ´Ù¸¥ Àå±âÀÇ ¹ÝÀÀÀ» º¼ ¼ö°¡ ÀÖ´Ù. ¼ö¿ëü´Â ´ÙÀ½°ú °°´Ù.
  
    -¾ËÆÄ¼ö¿ëü(alpha-receptor): ¸»ÃÊÇ÷°üÀÇ ¼öÃà, ±â°üÁöÀÇ ¼öÃà, µ¿°øÀÇ ±ÙÀ°ÀÇ ¼öÃà
  
    -º£Å¸1¼ö¿ëü(beta 1-receptor): ½ÉÀå¿¡ Á¸ÀçÇϴ ¼ö¿ëü, ½ÉÀåÀ» »¡¸® ¶Ù°ÔÇϴ ¿ªÇÒÀ» ÇÑ´Ù.
  
    -º£Å¸2¼ö¿ëü(beta 2-receptor): Ç÷°üÀÇ ÀÌ¿Ï, ±â°üÁöÀÇ ÀÌ¿Ï, Áï °¢ Àå±âµéÀº ±× Àå±â°¡ °¡Áö°í Àִ ±³°¨½Å°æÀÇ ¼ö¿ëü¿¡ µû¶ó ±³°¨½Å°æÀÇ ÈïºÐ(±³°¨½Å°æ ¸»´Ü¿¡¼­ÀÇ epinephrineÀÇ ºÐºñ)¿¡ ´ëÇÑ ¹ÝÀÀÀÌ ´Þ¶óÁø´Ù(¿¹-±³°¨½Å°æÀÌ ÈïºÐ½Ã¿¡ beta 1-¼ö¿ëü¸¦ °¡Áö°í Àִ ½ÉÀåÀº »¡¸® ¶Ù°Ô µÈ´Ù. ±³°¨½Å°æ ÈïºÐ½Ã¿¡ µ¿°øÀÇ ±ÙÀ°ÀÌ ¼öÃàÇØ¼­ µ¿°øÀÇ Å©±â°¡ Ä¿Áø´Ù)
  
  2.ºÎ±³°¨½Å°æ°è(parasympathetic nervous system)-±³°¨½Å°æ°ú ¹Ý´ë·Î ÀÛ¿ëÇÑ´Ù. Áï »ç¶÷ÀÌ Á¹¸®°Å³ª ½¯ °æ¿ì¿¡ ÈïºÐÇÑ´Ù. ºÎ±³°¨½Å°æÀÌ ÈïºÐÇÒ ¶§¿¡´Â ½Å°æÀÇ ¸»´Ü¿¡¼­ ¾Æ¼¼Ä¥Äݸ°ÀÇ ºÐºñ°¡ ÀϾ°í À̰ÍÀ¸·Î ÀÎÇØ¼­ °¢ Àå±âÀÇ º¯È­°¡ ÀϾ´Ù.
¿µ¹® TNM staging system ÇÑ±Û Á¾¾çº´±âºÐ·ù°èÅë
¼³¸í   
  Á¾¾çÀÇ º´±â(stage)¸¦ °áÁ¤Çϴ ÇÑ ¹æ¹ý.
  
  T´Â Tumor(Á¾¾ç)¸¦ ¶æÇϸ砿ø¹ßº´ÅÍÀÇ Å©±â, ÁÖÀ§Á¶Á÷À¸·ÎÀǠħÀ±Á¤µµ µî¿¡ µû¶ó T1, T2, T3, T4(¼ýÀÚ°¡ ³ôÀ» ¼ö·Ï ÁÖÀ§·Î Ä§À±ÀÌ ¸¹´Ù) µîÀ¸·Î ³ª´«´Ù.
  
  NÀº Node(¸²ÇÁÀý)¸¦ ¶æÇϸç Ä§¹üµÈ ¸²ÇÁÀýÀÇ °¹¼ö, Å©±â, À§Ä¡ µî¿¡ µû¶ó N1, N2, N3 µîÀ¸·Î ³ª´«´Ù.
  
  MÀº Metastasis(ÀüÀÌ)¸¦ ¶æÇϸ砿ø°ÝÀüÀÌÀÇ À¯¹«¿¡ µû¶ó M0, M1 µîÀ¸·Î ³ª´«´Ù.
  
  ÀÌ»óÀÇ ¹æ¹ýÀ¸·Î T, N, MÀÌ °áÁ¤µÇ¸é À̵éÀ» Á¶ÇÕÇÏ¿© ÃÖÁ¾ÀûÀΠº´±â¸¦ °áÁ¤ÇÑ´Ù. ÀÌ·¸°Ô °áÁ¤µÈ º´±â´Â Ä¡·á ¹æÄ§ °áÁ¤°ú ¿¹ÈÄ ÆÇ´Ü¿¡ ¸Å¿ì Áß¿äÇÏ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • control system
    Á¦¾îÀåÄ¡
  • countercurrent system
    ¿ª·ù°è
  • culture system
    ¹è¾ç½Ã½ºÅÛ
  • cytochrome P-450 system
    ½ÃÅäÅ©·ÒP-450½Ã½ºÅÛ
  • cardiovascular system
    ½ÉÀåÇ÷°ü°èÅë, ½ÉÇ÷°ü°è
  • case payment system
    Æ÷°ý¼ö°¡Á¦
  • central nervous system
    ÁßÃ߽Űæ°èÅë, ÁßÃ߽Űæ°è
  • drug delivery system
    ¾à¹°Àü´Þü°è
  • dynamic system
    µ¿Àû°èÅë
  • digestive system
    ¼ÒÈ­°èÅë, ¼ÒÈ­°è
  • display system
    Ç¥½ÃÀåÄ¡
  • exteroceptive nervous system
    ¿Ü¼ö¿ë½Å°æ°è
  • extrapyramidal motor system
    ÇǶó¹Ìµå¹Ù±ù±æ¿îµ¿°è, Ãßü¿Ü·Î¿îµ¿°è
  • electro-optical system
    Àü±â±¤Çкм®°è
  • emergency medical service system
    ÀÀ±ÞÀÇ·á¼­ºñ½ºÃ¼°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • central piping system
    Áß¾Ó¹è°ü½Ã¼³
  • chemoreception system
    È­Çмö¿ë°è
  • circle absorption system
    ¼øÈ¯Èí¼ö½Äȸ·Î
  • circuit system
    ¼øÈ¯½Äȸ·Î
  • circulatory system
    ¼øÈ¯°èÅë
  • closed drainage system
    ´ÝÈû¹èÃâÀåÄ¡
  • clotting system
    ÀÀ°í°èÅë
  • collecting system
    ÁýÇÕ°è
  • combined system disease
    º¹ÇÕ°èÅ뺴
  • community water system
    Áö¿ª»çȸ±Þ¼ö½Ã¼³
  • complement system
    µµ¿òü°èÅë, º¸Ã¼°èÅë
  • conduction system
    ÈïºÐÀüµµ°è
  • control system
    Á¦¾îÀåÄ¡
  • cortically originating extrapyamidal system
    °ÑÁú±â¿øÇǶó¹Ô¹Ù±ù·Î°èÅë, ÇÇÁú¹ßÃßü¿Ü·Î°è
  • countercurrent system
    ¿ª·ù°è
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Apgar scoring system
    Apgar Á¡¼öÆò°¡¹ý
  • Bactec system
    ¹ÚÅØ°èÅë
  • Control system
    Á¶Àý°è(ðàï½Í§)
  • DNA repair system
    DNA ·¹Çø®ÄÉÀ̽º ½Ã½ºÅÛ.
  • DNA repair system
    DNA º¸¼ö±â±¸.
  • DOS (disk operating system)
    µð½ºÅ© ¿î¿µ üÁ¦
  • Diego blood group system
    µð¿¡°í Ç÷¾×Çü°è
  • Duffy system
    ´õÇǰè.
  • Female reproductive system
    ¿©¼º(Ò³àõ)»ý½Ä±â°ü(ßæãÖÐïί)
  • Fibrinolytic system
    ¼¶À¯¼Ò¿ëÇØ°è(¡­Ìõ)
  • Fisher-Race system
    Çǽ¬-·¹À̽º ½Ã½ºÅÛ
  • General anesthesia, reticular activating system and.
    Àü½Å¸¶Ãë(îïãóئö­), ¸Á»óüȰ¼ºÈ­°è(ØÑßÒô÷üÀàõûùͧ)
  • Glycogen-lactic acid system
    ±Û¸®ÄÚ°Õ-¶ôÆ®»ê°è
  • Haversian system
    »À ´ÜÀ§<°ñ¿ø>, ÇϹö½º °èÅë(¡­Í§÷Ö).
  • Haversian system
    »À´ÜÀ§<°ñ¿ø>, ÇϹö½º°è Åë(¡­Í§÷Ö).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • gastrointestinal manometry
  • gastrointestinal motility
    À§Àå°ü¿îµ¿(êÖíóηê¡ÔÑ).
  • gastrointestinal motility
    À§Àå°ü¿îµ¿.
  • gastrointestinal mucormycosis
    À§Àå°ü ¸ð±ÕÁõ
  • gastrointestinal obstruction
    À§Àå°üÆó¼â (Áõ).
  • gastrointestinal polyposis
    À§Àå¿ëÁ¾Áõ
  • gastrointestinal reflex
    À§¼ÒÀå(êÖá³íó)¹Ý»ç(ÚãÞÒ).
  • gastrointestinal reflex
    À§¼ÒÀå¹Ý»ç.
  • gastrointestinal series =GI series
    ¹æ»ç À§Àå°üÁ¶¿µ¼ú.
  • gastrointestinal sphincter
    À§Àå°ý¾à±Ù
  • gastrointestinal syndrome
    À§Àå°üÁõÈıº
  • gastrointestinal tract
    À§Àå°ü
  • gastrointestinal tract =alimentary t.
    À§Àå°ü(êÖ Î·).
  • gastrointestinal tract =alimentary t.
    À§Àå°ü(êÖíóη).
  • gastrointestinal tuberculosis
    À§Àå°ü°áÇÙ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • intrinsic system
    ³»ÀÎ(Ò®ì×) ½Ã½ºÅÛ
  • isolated system
    °Ý¸®(̰×î)½Ã½ºÅÛ
  • Kovats retention index system
    ÄÚ¹ÙÆ® ü·ù(ôò׺) Áö¼ö(ò¦â¦)½Ã½ºÅÛ
  • K system
    K ½Ã½ºÅÛ
  • leiotonin system
    ¶óÀÌ¿ÀÅä´Ñ ½Ã½ºÅÛ
  • MN blood group system
    MN½Ä(ãÒ)Ç÷¾×Çü(úìäûúþ)
  • model system
    ¸ðµ¨½Ã½ºÅÛ
  • multienzyme system
    ´ÙÈ¿¼Ò(Òýý£áÈ)½Ã½ºÅÛ
  • multisubstrate enzyme system
    ´Ù±âÁúÈ¿¼Ò(ÒýѨòõý£áÈ) ½Ã½ºÅÛ
  • open-circuit system
    °³¹æÈ¸·Î(ËÒÛ¯üÞÖØ) ½Ã½ºÅÛ
  • open system
    °³¹æ(ËÒÛ¯) ½Ã½ºÅÛ
  • optical system
    ±¤(ÎÃ) ½Ã½ºÅÛ
  • phosphotransferase system
    Æ÷½ºÆ÷Æ®¶õ½ºÆÛ·¹À̽º ½Ã½ºÅÛ
  • protein-synthesizing system
    ´Ü¹éÁú ÇÕ¼º(Ó±ÛÜòõùêà÷) ½Ã½ºÅÛ
  • repressible system
    ¾ïÁ¦¼º ½Ã½ºÅÛ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
IDA   1) Imino-Diacetic Acid
  2) Iron Deficiency Anemia
   &nb...
ASGE American Society for Gastrointestinal Endoscopy
AUGH acute upper gastrointestinal hemorrhage
GE gastric empyting; gastroemotional; gastroenteritis; gastroenterology; gastroenterostomy; gastroesoph...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
GIQLI Gastrointestinal Quality of Life Index
GSRS Gastrointestinal Symptom Rating Scale
GITSG Gastrointestinal Tumor Study Group
GAN Gastrointestinal autonomic nerve
UGI Upper gastrointestinal
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • conduction system
    ÈïºÐ Àüµµ°è
  • control system
    Á¶Àý°è
  • corticospinal system
    ÇÇÁú ô¼ö°è
  • countercurrent system
    ¿ª·ù°è, ´ëÇâ·ù°è
  • crystal system
    Á¤°è, °áÁ¤°è
  • cyclic AMP system
    ȯ»ó AMP °è
  • descending inhibitory system
    ÇÏÇà ¾ïÁ¦°è
  • digestive system
    ¼ÒÈ­±â °èÅë
  • disease of the lymphreticular system
    ¸²ÇÁ ¼¼¸Á³»ÇǰèÀÇ Áúȯ
  • DNA repair system
    DNA º¸¼ö ±â±¸
  • dopaminergic system
    µµÆÄ¹Î ü°è
  • drug delivery system
    ¾à¹° Åõ¿©±â, ¾à¹° Åõ¿© üÁ¦, ¾à¹° Àü´Þ ü°è
  • dual foil system
    ÀÌÁß ¹Ú¸· ±¸Á¶
  • ductal system
    µµ°ü°è
  • dynamic system
    µ¿Àû °èÅë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
anti-arrhythmia agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
(12 Dec 1998)
anti-asthmatic agents Drugs that are used to treat asthma.
(12 Dec 1998)
anticarcinogenic agents Agents that reduce the frequency or rate of spontaneous or induced tumours independently of the mechanism involved. They differ from antineoplastic agent in that they prevent neoplasms from forming. The anticarcinogenic substances can be divided into three categories. The first consists of compounds that prevent the formation of carcinogens from precursor substances. The second group consists of "blocking agents" which inhibit carcinogenesis by preventing carcinogenic agents from reaching or reacting with critical target sites in the tissues. The third group is the "suppressor agents" which act by suppression of expression of neoplasia in cells previously exposed to carcinogens that would otherwise cause neoplasms.
(12 Dec 1998)
anticestodal agents Agents used to treat tapeworm infestations in man or animals.
(12 Dec 1998)
anticholesteraemic agents Substances that promote a reduction of blood cholesterol levels.
(12 Dec 1998)
anti-coagulant agents Medications, like heparin, used as blood-thinners to prevent blood clots and to maintain open blood vesssels.
(12 Dec 1998)
antidepressive agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several monoamine oxidase inhibitors are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (antidepressive agents, tricyclic) also appear to act through brain catecholamine systems. A third group (antidepressive agents, second-generation) is a diverse group of drugs including some that act specifically on serotonergic systems.
(12 Dec 1998)
antidepressive agents, second-generation A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
(12 Dec 1998)
antidepressive agents, tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
(12 Dec 1998)
anti-dyskinesia agents Drugs used in the treatment of movement disorders. most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of parkinson disease (antiparkinson agents) and those for the tardive dyskinesias.
(12 Dec 1998)
antifoaming agents Agents used to prevent the formation of foam or to treat flatulence or bloat.
(12 Dec 1998)
antifungal agents Agents destructive to fungi, suppressing their growth or reproduction, and effective against fungal infections. They differ from fungicides, industrial in that antifungal agents are restricted to action against fungi present in human or animal tissues.
(12 Dec 1998)
anti-HIV agents Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids.
(12 Dec 1998)
antihypertensive agents Drugs used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Among the antihypertensive agents are diuretics (especially diuretics, thiazide), adrenergic beta-antagonists, adrenergic alpha-antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents.
(12 Dec 1998)
anti-infective agents, local Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from disinfectants, which are used on inanimate objects.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • cold type system
    Äݵå ŸÀÌÇÁ ½Ã½ºÅÛ(³³È°ÀÚ³ª ¿­À» »ç¿ëÇÏÁö ¾Ê°í Çʸ§À» ÁÖü·ÎÇÑ »ç½ÄÈ­¿¡ ÀÇÇÑ Àμ⠰øÁ¤
  • container system
    ÄÁÅ×ÀÌ³Ê ¼ö¼Û¹æ½Ä
  • convict system
    ¡¿ª(À¯Çü)Á¦µµ
  • coupon system
    °æÇ°ºÎ ÆÇ¸Å¹ý
  • data base management system
    (Àü»ê)µ¥ÀÌÅͺ£À̽º °ü¸® ½Ã½ºÅÛ(¾à DBMS)
  • decimal system
    ½ÊÁø¹ý
  • decision support system
    (Àü»ê)(°æ¿µÀÇ)ÀÇ»ç °áÁ¤ Áö¿ø ½Ã½ºÅÛ
  • delayed time system
    (ÀüÀÚ)½Ã°£ Áö¿¬(ÃàÀû)¹æ½Ä
  • digestive system
    (ÇØ)¼ÒÈ­±â °èÅë(ÀÔ,À§,Àå µî)
  • domestic system
    °¡³» °ø¾÷ Á¦µµ
  • duples system
    (Àü»ê)º¹½Ä ½Ã½ºÅÛ(2´ëÀÇ ÄÄÇ»Å͸¦ ¼³Ä¡Ç쵂 Çϳª´Â ¿¹ºñ¿ë)
  • early-warning system
    (±º)(ÇÙ°ø°Ý¿¡ ´ëÇÑ)Á¶±â °æº¸ Á¶Á÷
  • factory system
    °øÀå Á¦µµ
  • farm system
    Á¦2±º ¸®±× ÇÕµ¿ ¿î¿µÁ¦
  • feudal system
    ºÀ°Ç Á¦µµ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á